EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer research hub

Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated with Amivantamab, an EGFR-MET bispecific antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study

This study looks at ways to prevent infusion reactions in people with advanced lung cancer receiving a new combination of medicines. Researchers are testing different medications given before treatment to see if they can reduce side effects when the main cancer drug is given through a drip.